| Autor: |
Uleer C; Gynecologic Oncology Group Practice Hildesheim, Neu-Isenburg, Germany., Yazdan-Pourfard J, Holland B, Karl-Friedrich B, Moisidis-Tesch C, von Minckwitz G |
| Jazyk: |
angličtina |
| Zdroj: |
Breast care (Basel, Switzerland) [Breast Care (Basel)] 2012 Feb; Vol. 7 (1), pp. 45-47. Date of Electronic Publication: 2012 Feb 21. |
| DOI: |
10.1159/000336536 |
| Abstrakt: |
BACKGROUND: Since the introduction of trastuzumab into the treatment of Her-2/neu-positive metastatic breast cancer, cases of long-term survival have become more frequent. Even after tumor progression, trastuzumab seems to retain its antitumor activity which is potentiated by the combination with a chemotherapeutic agent. CASE REPORT: We are reporting about the unusual clinical course of a young patient with Her-2/neu-positive breast cancer, who experienced progression of pulmonary and bone metastases under treatment with trastuzumab. Upon progression, a combination therapy with capecitabine/trastuzumab was initiated, and a partial remission was achieved which has continued for over 4 years. CONCLUSION: This unusual clinical course shows that continuing trastuzumab-based therapy beyond progression is a safe, effective, and well-tolerated option which can induce long-term remissions in some patients with Her-2/neu-positive metastatic breast cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
